CN106621003A - Drug balloon catheter and preparation method and application thereof - Google Patents
Drug balloon catheter and preparation method and application thereof Download PDFInfo
- Publication number
- CN106621003A CN106621003A CN201610988119.3A CN201610988119A CN106621003A CN 106621003 A CN106621003 A CN 106621003A CN 201610988119 A CN201610988119 A CN 201610988119A CN 106621003 A CN106621003 A CN 106621003A
- Authority
- CN
- China
- Prior art keywords
- balloon catheter
- drug
- medicine
- medicinal balloon
- sacculus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 99
- 229940079593 drug Drugs 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 239000003018 immunosuppressive agent Substances 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 8
- 239000011248 coating agent Substances 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims abstract description 7
- 229920000642 polymer Polymers 0.000 claims description 15
- 239000002861 polymer material Substances 0.000 claims description 11
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 9
- 238000003618 dip coating Methods 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- 229960004397 cyclophosphamide Drugs 0.000 claims description 8
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 claims description 6
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 230000003356 anti-rheumatic effect Effects 0.000 claims description 5
- 239000003435 antirheumatic agent Substances 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- -1 polyethylene terephthalate Polymers 0.000 claims description 5
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 239000004677 Nylon Substances 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000003862 glucocorticoid Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920001778 nylon Polymers 0.000 claims description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 3
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 3
- 229920000151 polyglycol Polymers 0.000 claims description 3
- 239000010695 polyglycol Substances 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 229920002614 Polyether block amide Polymers 0.000 claims description 2
- 230000001028 anti-proliverative effect Effects 0.000 claims description 2
- 150000002596 lactones Chemical class 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 239000004814 polyurethane Substances 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000003902 lesion Effects 0.000 abstract description 9
- 208000037803 restenosis Diseases 0.000 abstract description 7
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 208000031481 Pathologic Constriction Diseases 0.000 abstract description 5
- 230000002792 vascular Effects 0.000 abstract description 5
- 208000025747 Rheumatic disease Diseases 0.000 abstract description 4
- 229940127089 cytotoxic agent Drugs 0.000 abstract description 4
- 239000002254 cytotoxic agent Substances 0.000 abstract description 4
- 230000000552 rheumatic effect Effects 0.000 abstract description 4
- 230000036262 stenosis Effects 0.000 abstract description 2
- 208000037804 stenosis Diseases 0.000 abstract description 2
- 230000005911 anti-cytotoxic effect Effects 0.000 abstract 2
- 210000004204 blood vessel Anatomy 0.000 description 13
- 239000000203 mixture Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- 206010048628 rheumatoid vasculitis Diseases 0.000 description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 description 6
- 230000003156 vasculitic effect Effects 0.000 description 6
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 229960002170 azathioprine Drugs 0.000 description 4
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 230000001861 immunosuppressant effect Effects 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 206010047249 Venous thrombosis Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010002921 Aortitis Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 230000000781 anti-lymphocytic effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 208000007474 aortic aneurysm Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 208000001297 phlebitis Diseases 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002915 Aortic valve incompetence Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010007687 Carotid artery stenosis Diseases 0.000 description 1
- 206010061751 Cerebrovascular stenosis Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- YPINZEGNLULHHT-UHFFFAOYSA-N Fujimycin Natural products COC1CC(CCC1O)C=C(/C)C2OC(=O)C3CCCCCN3C(=O)C(=O)C4(O)OC(C(CC4C)OC)C(OC)C(C)CC(=CC(CC=C)C(=O)CC(O)C2C)C YPINZEGNLULHHT-UHFFFAOYSA-N 0.000 description 1
- 208000032844 Hemoperitoneum Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010072563 Peripheral artery stenosis Diseases 0.000 description 1
- 208000031853 Peritoneal haemorrhage Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 206010053648 Vascular occlusion Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 201000002064 aortic valve insufficiency Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000006170 carotid stenosis Diseases 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 201000003278 cryoglobulinemia Diseases 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 201000004595 synovitis Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 208000021331 vascular occlusion disease Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0009—Making of catheters or other medical or surgical tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention provides a drug balloon catheter and a preparation method and application thereof. The drug balloon catheter comprises a balloon, a delivery catheter communicated with the balloon and a drug coating on the surface of the balloon, wherein the drug coating contains an anti-cytotoxic drug or an immunosuppressor drug for treating rheumatic and rheumatoid diseases. The drug coating is the anti-cytotoxic drug or the immunosuppressor drug for treating the rheumatic and rheumatoid diseases so that vascular inflammatory stenosis caused by parts of the rheumatic and rheumatoid diseases can be solved. The drug coating carried by the balloon centrally acts on the periphery of the lesion vessel after the balloon reaches the lesion vessel, accordingly the local drug concentration of a lesion is achieved, further an ideal treating effect is obtained, and meanwhile restenosis is prevented.
Description
Technical field
The invention belongs to technical field of medical instruments, is related to a kind of medicinal balloon catheter and its preparation method and application, especially
It is related to a kind of antirheumatic angiostenosiss medicinal balloon catheter and its preparation method and application.
Background technology
Rheumatism and rheumatoid arthritis (RA) it is a kind of with articular synovitis systematicness rheumatoid vasculitises be characterized
Chronic generalized autoimmune disease, rheumatism is locally or systemically class disease, its pathological change, except relevant muscle is closed
Outside section pathological changes, the inflammation of blood vessel changes, angiostenosiss, and thrombosiss are so that vascular occlusion, blood flow reduction is also a kind of main
Case characteristic.Rheumatism and rheumatoid vasculitis (RV) are a serious complication, sickness rate 1%-5% clinically,
But postmortem research shows up to 25% ratio, is more common in pathomechanism of the course of disease compared with elder, rheumatism and rheumatoid vasculitis
Possibly anti-endotheliocyte body is combined rear activating complement with corresponding endotheliocyte or by mediating the mediation of body dependent cell
Cytotoxicity and cause endothelial cell injury, immune complex activation tube wall, inducing cell release multiple protein enzyme starts solidifying
Blood mechanism, forms thrombosis.Therefore have many rheumatoid factor with high concentration of vasculitic rheumatoid arthritis patients, low complement blood
There are a large amount of immune complexs in disease, cryoglobulinemia and serum.Speed with erythrocyte sedimentation rate with vasculitic patient is more, it is lean
The Novel presentation such as blood, thrombocytosiss and albumin, globulin concentration reduction, while the inflammatory cell leaching of rheumatoid vasculitis
Moisten around blood vessel, Ink vessel transfusing, crust hypertrophy or blood vessel holostrome inflammatory become, and cause luminal stenosis to block, and blood vessel wall cellulose sample becomes
Property even necrosis, Aneurysmformation, Rupture haemorrhag or fibrosiss etc..
Clinically there is patient RV in 10%-15% in Cardiac Involvemant, can invade coronal this sick First presentation more
Small artery, occasionally involves main coronary artery.Its characteristics of lesion is blood vessel wall and circumvascular inflammatory cell infiltration, immune globulin
The white calmness in blood vessel wall；There can be thrombosiss, but exist without atherosclerotic plaque, pathological changes severe patient can cause myocardium stalk
Extremely.It is generally acknowledged that clinically the concurrent angina pectoriss of rheumatoid coronaritises and (or) acute myocardial infarction person is rare.However, one
The Review literature of 169 patient's RA postmortems is disclosed, and coronaritises are with the direct cause of death that various myocardial infarctions are 10 patients
(5.9%).Therefore, coronary artery inflammation is not as expected so rare.The fatal complication of some other cardiovascular of RV
Also include aortitiss, aortic aneurysm and Acute Aortic lobe incompetence, the rupture of Visceral artery tumor is with hemoperitoneum etc..It is true
On, all rheumatic aortitis cases are that the aortic aneurysm in ascending aorta occurs, and with aortic incompetence.RA
Often involve blood vessel, but it is more with tremulous pulse, and there is phlebitis and the less report of venous thrombosis person.Zhang Suping etc. reports 1
RA patient merges Shuan Ce popliteal venous thrombosis, and patient is without operation, wound, long-term bed, varicosis and takes contraceptive etc.
The risk factor of induction venous thrombosis, thus it is speculated that its thrombotic possible cause is that immunoglobulin and complement are in blood vessel
Wall is deposited, and causes endothelial cell damage, causes phlebitis.
Rheumatism and rheumatoid vasculitic stricture disease, including heart and peripheral arterial are due to rheumatism and rheumatoid blood
Around the inflammatory cell infiltration blood vessel of Guan Yan, Ink vessel transfusing crust hypertrophy or blood vessel holostrome inflammatory become, and cause vessel lumen narrow stifled
Plug, such as coronary stricture, cerebrovascular stenosis, carotid artery stenosises, iliac artery be narrow and femoral artery stenosis.
The narrow method of traditional treatment rheumatism and rheumatoid vascular inflammatory is mainly using heavy dose of glucocorticoid
Use in conjunction immunosuppressive drug, including azathioprine (AZA) and cyclophosphamide (CTX).At present mainly by venoclysises or
Oral such medicine carries out systemic administration treatment, but therapeutic effect is undesirable, and the utilization rate of medicine is not high, has particularly been formed
Narrow blood vessel is poor to this systemic drug therapeutic response.The method of stenotic lesion blood vessel Stent Implantation, because of its active rheumatism
Continue to result in restenosis rate very high, long-term effect is not good, make to be faced a difficult selection during the Clinical practice technology.
Therefore, in the art, it is desired to be able to find a kind of rheumatism that can improve long-term effect and rheumatoid blood vessel
Struvite narrow effectively treatment method.
The content of the invention
For the deficiencies in the prior art, it is an object of the invention to provide a kind of medicinal balloon catheter and preparation method thereof and
Using.
It is that, up to this purpose, the present invention is employed the following technical solutions：
On the one hand, the present invention provides a kind of medicinal balloon catheter, and the medicinal balloon catheter is connected including sacculus with sacculus
Delivery conduit and balloon surface medication coat, the medication coat contains the anti-thin for the treatment of rheumatism and atrophic diseases
Cytotoxic drugs or immune suppressant drug.
The medication coat of the present invention is the anti-cell drug toxicity or immunosuppressant for treating rheumatism and atrophic diseases
Medicine, it is possible to resolve part rheumatism and atrophic diseases cause vascular inflammatory narrow, sacculus is reached after lesion vesselses, its carrying
Medication coat concentrate and act on around lesion vesselses, so as to reach pathological changes topical remedy high concentration, and then obtain Preferred effects,
Prevent restenosiss simultaneously.
In the present invention, the anti-cell drug toxicity or immune suppressant drug of the treatment rheumatism and atrophic diseases
In NSAID (non-steroidal anti-inflammatory drug), cyclophosphamide or glucocorticoid any one or at least two combination.
Cytotoxic drug is the medicine that can effectively kill immunocyte and suppress its propagation, and immunosuppressant is to body
The inhibited medicine of immunoreation, (such as T cell and B cell macrophage are thin to suppress cell relevant with immunoreation
Born of the same parents) propagation and function, reduce antibody mediated immunity reaction.This kind of medicine mainly include glucocorticoidss, microbial metabolic products,
Antimetabolite, polyclone and monoclonal anti lymphocyte antibody, the class of alkylating agents 5.Cytotoxic drug of the present invention includes
But it is not limited to cyclophosphamide or chlormethine.
Immunosuppressant of the present invention includes but is not limited to cortisone, prednisone, cyclosporin, fujimycin 506, anti-
Metabolite, such as azathioprine, Ismipur, antilymphocyte globulin, OKT3 (CD 3-resisting monoclonal antibody) or cyclophosphamide
In any one or at least two combination.
In the present invention, the anti-cell drug toxicity or immune suppressant drug of the treatment rheumatism and atrophic diseases
Can be used in combination with its pharmaceutically active auxiliary agent.
Preferably, the pharmaceutically active auxiliary agent selected from anti-proliferative drugs, promote again endothelialization medicine, anti-cell migration medicine or
Any one or at least two medicine activity components in intercellular matrix regulator are used in combination.Can be used for treat rheumatism and
Rheumatism and rheumatoid vasculitises that atrophic diseases cause and the vessel lumen stricture disease that causes, and prevent stenter to implant
The generation of restenosiss phenomenon afterwards.
In the present invention, the drug loading of the medication coat is 10～500 μ g/cm2, such as 12 μ g/cm2、15μg/cm2、
18μg/cm2、20μg/cm2、25μg/cm2、30μg/cm2、40μg/cm2、50μg/cm2、80μg/cm2、100μg/cm2、120μg/
cm2、150μg/cm2、180μg/cm2、200μg/cm2、250μg/cm2、280μg/cm2、300μg/cm2、350μg/cm2、400μg/
cm2、450μg/cm2Or 480 μ g/cm2, preferred 50-200 μ g/cm2, further preferred 80-150 μ g/cm2。
In the present invention, the medication coat includes biostable polymer material, it is preferable that the biological stability
Polymeric material is polylactic acid-polyglycol block polymer, polyethylene glycol caprolactone block polymer or polylactic acid-glycolic
In acetic acid copolymer any one or at least two combination.
Preferably, the thickness of the medication coat is 1～50 μm, such as 2 μm, 5 μm, 8 μm, 10 μm, 13 μm, 15 μm, 18 μ
M, 20 μm, 23 μm, 25 μm, 28 μm, 30 μm, 33 μm, 35 μm, 38 μm, 40 μm, 42 μm, 45 μm or 48 μm, preferred 5-20 μm.
Preferably, in the medication coat medicine percentage by weight be 1～50%, such as 2%, 5%, 8%, 10%,
13%th, 15%, 18%, 20%, 22%, 25%, 28%, 30%, 33%, 35%, 38%, 40%, 42%, 45% or 48%,
It is preferred that 10-20%.
In the present invention, a diameter of 0.8～7.0mm of the sacculus, such as 1mm, 1.5mm, 1.8mm, 2mm, 2.5mm,
2.8mm, 3mm, 3.3mm, 3.5mm, 3.8mm, 4mm, 4.5mm, 4.8mm, 5mm, 5.5mm, 5.8mm, 6mm, 6.3mm, 6.5mm or
6.8mm, the length of sacculus is 8～120mm, such as 9mm, 12mm, 15mm, 20mm, 30mm, 40mm, 50mm, 60mm, 70mm,
80mm, 90mm, 100mm or 110mm.
In the present invention, the sacculus is by selected from polyethylene (PE), polyethylene terephthalate (PET), nylon
(Nylon) any one or at least two material, in Pebax, polyurethane (PU), polypropylene (PP) or latex is made.
On the other hand, the invention provides the preparation method of the medicinal balloon catheter, methods described is：By medicine or medicine
Thing is combined and biostable polymer material mixing, and by spraying or dip-coating even spread to balloon surface the medicine is obtained
Foley's tube；Or first by biostable polymer material by spraying or dip-coating even spread to balloon surface, then will
Medicine or drug regimen adsorb in coating surface, obtain the medicinal balloon catheter.
The medicinal balloon catheter that the present invention is prepared can be used to treat rheumatism and rheumatoid vasculitic angiostenosiss,
Compared with the method for traditional treatment rheumatism and rheumatoid vasculitic angiostenosiss, the medicinal balloon catheter is formed for for it
Narrow vascular treatment effect is good, and administration targeting is good, and utilization ratio of drug is high, and persistence is strong, reduces continuing because of active rheumatism
The high risk of caused restenosis rate, medium-long term effect is good, with good clinical and commercial promise.
On the other hand, the invention provides described medicinal balloon catheter answering in antirheumatic angiostenosiss apparatus
With.The medicinal balloon catheter of the present invention can play it as the therapeutic device or medical material for antirheumatic angiostenosiss
Antirheumatic and prevent the dual function of angiostenosiss.
Relative to prior art, the invention has the advantages that：
The medication coat of the present invention is the anti-cell drug toxicity or immunosuppressant for treating rheumatism and atrophic diseases
Medicine, it is possible to resolve part rheumatism and atrophic diseases cause vascular inflammatory narrow, sacculus is reached after lesion vesselses, its carrying
Medication coat concentrate and act on around lesion vesselses, so as to reach pathological changes topical remedy high concentration, and then obtain Preferred effects,
Prevent restenosiss simultaneously.
Specific embodiment
Technical scheme is further illustrated below by specific embodiment.Those skilled in the art should be bright
, the embodiment be only to aid in understand the present invention, be not construed as to the present invention concrete restriction.
Embodiment 1
In the present embodiment, medicinal balloon catheter includes the delivery conduit that connects with sacculus of sacculus and balloon surface
Medication coat, medication coat contains cortisone and biostable polymer Poly(D,L-lactide-co-glycolide, its preparation method
For：Medicine and biostable polymer material Poly(D,L-lactide-co-glycolide are dissolved in solvent, mixing is mixed to get
Thing, by the mixture by spraying or dip-coating even spread to balloon surface, after solvent volatilization, medicine stays in balloon surface,
So as to obtain the medicinal balloon catheter.The medication coat gross thickness of the medicinal balloon is 10 μm, total wherein shared by active medicine
Percentage by weight is 10%, a diameter of 2mm of the sacculus, and the length of sacculus is 10mm.
Embodiment 2
In the present embodiment, medicinal balloon catheter includes the delivery conduit that connects with sacculus of sacculus and balloon surface
Medication coat, medication coat contains cyclophosphamide and biostable polymer polylactic acid-polyglycol block polymer, its system
Preparation Method is：Medicine and biostable polymer material are dissolved in solvent, mixture is mixed to get, the mixture is passed through
, to balloon surface, after solvent volatilization, medicine stays in balloon surface, so as to obtain the medicine ball for spraying or dip-coating even spread
Ductus bursae.The medication coat gross thickness of the medicinal balloon is 5 μm, and wherein total weight percent shared by active medicine is 5%, wherein
Total weight percent shared by active medicine is 10%, a diameter of 7mm of the sacculus, and the length of sacculus is 100mm.
Embodiment 3
In the present embodiment, medicinal balloon catheter includes the delivery conduit that connects with sacculus of sacculus and balloon surface
Medication coat, medication coat contains the mixture and biostable polymer polylactic acid of cyclophosphamide and prednisone-poly- second
Diol block polymer, its preparation method is：Pharmaceutical composition and biostable polymer material are dissolved in solvent, are mixed
Mixture is obtained, by the mixture by spraying or dip-coating even spread to balloon surface, after solvent volatilization, medicine stays in ball
Capsule surface, so as to obtain the medicinal balloon catheter.The medication coat gross thickness of the medicinal balloon is 20 μm, wherein active medicine
Shared total weight percent be 1%, wherein total weight percent shared by active medicine be 10%, the sacculus it is a diameter of
0.8mm, the length of sacculus is 8mm.
Embodiment 4
In the present embodiment, medicinal balloon catheter includes the delivery conduit that connects with sacculus of sacculus and balloon surface
Medication coat, medication coat contains azathioprine and biostable polymer polyethylene glycol caprolactone block polymer,
Its preparation method is：Medicine and biostable polymer material are dissolved in solvent, mixture are mixed to get, by the mixture
By spraying or dip-coating even spread to balloon surface, after solvent volatilization, medicine stays in balloon surface, so as to obtain the medicine
Thing foley's tube.The medication coat gross thickness of the medicinal balloon is 30 μm, and wherein total weight percent shared by active medicine is
50%, wherein total weight percent shared by active medicine is 10%, a diameter of 4mm of the sacculus, and the length of sacculus is
120mm。
Embodiment 5
In the present embodiment, medicinal balloon catheter includes the delivery conduit that connects with sacculus of sacculus and balloon surface
Medication coat, medication coat contains the mixture and biostable polymer polyethylene glycol of cyclophosphamide and prednisone
Caprolactone block polymer, its preparation method is：By pharmaceutical composition and biostable polymer material polyethylene glycol
Lactone block polymer is dissolved in solvent, is mixed to get mixture, by the mixture by spraying or dip-coating even spread to ball
Capsule surface, after solvent volatilization, medicine stays in balloon surface, so as to obtain the medicinal balloon catheter.The medicine of the medicinal balloon
Thing total coating thickness is 10 μm, and wherein total weight percent shared by active medicine is 10%, wherein gross weight shared by active medicine
Percentage ratio is 20%, a diameter of 2mm of the sacculus, and the length of sacculus is 20mm.
Medicinal balloon catheter prepared by embodiment of the present invention 1-5 is used to treat rheumatism and rheumatoid vasculitic is narrow
When, its therapeutic effect is good, and administration targeting is good, and utilization ratio of drug is high, and persistence is strong, can reduce continuing to result in because of active rheumatism
The high risk of restenosis rate, medium-long term effect is good, with good clinical and commercial promise.
Applicant states that the present invention illustrates medicinal balloon catheter of the present invention and preparation method thereof by above-described embodiment
And application, but the invention is not limited in above-described embodiment, that is, do not mean that the present invention has to rely on above-described embodiment ability real
Apply.Person of ordinary skill in the field it will be clearly understood that any improvement in the present invention, to the equivalent of each raw material of product of the present invention
Replacement and addition, the selection of concrete mode of auxiliary element etc., within the scope of all falling within protection scope of the present invention and disclosure.
Claims (10)
1. a kind of medicinal balloon catheter, it is characterised in that the medicinal balloon catheter includes that the conveying that sacculus is connected with sacculus is led
The medication coat of pipe and balloon surface, the medication coat contains the anti-cell toxicity medicine for the treatment of rheumatism and atrophic diseases
Thing or immune suppressant drug.
2. medicinal balloon catheter according to claim 1, it is characterised in that the treatment rheumatism and atrophic diseases
Anti-cell drug toxicity or immune suppressant drug are any one in NSAID (non-steroidal anti-inflammatory drug), cyclophosphamide or glucocorticoid
Kind or at least two combination.
3. medicinal balloon catheter according to claim 1 and 2, it is characterised in that the treatment rheumatism and rheumatoid disease
The anti-cell drug toxicity or immune suppressant drug of disease is used in combination with its pharmaceutically active auxiliary agent；
Preferably, the pharmaceutically active auxiliary agent is selected from anti-proliferative drugs, promotees endothelialization medicine, anti-cell migration medicine or cell again
Between any one or at least two medicine activity components in substrate regulator.
4. the medicinal balloon catheter according to any one of claim 1-3, it is characterised in that the load medicine of the medication coat
Measure as 10～500 μ g/cm2, preferred 50-200 μ g/cm2, further preferred 80-150 μ g/cm2。
5. the medicinal balloon catheter according to any one of claim 1-4, it is characterised in that the medication coat includes life
Thing stable polymers material；
Preferably, the biostable polymer material be polylactic acid-polyglycol block polymer, polyethylene glycol
In lactone block polymer or Poly(D,L-lactide-co-glycolide any one or at least two combination.
6. the medicinal balloon catheter according to any one of claim 1-5, it is characterised in that the thickness of the medication coat
For 1～50 μm, preferred 5-20 μm；
Preferably, the percentage by weight of medicine is 1～50% in the medication coat, preferred 10-20%.
7. the medicinal balloon catheter according to any one of claim 1-6, it is characterised in that the sacculus it is a diameter of
0.8～7.0mm, the length of sacculus is 8～120mm.
8. the medicinal balloon catheter according to any one of claim 1-7, it is characterised in that the sacculus is by selected from poly- second
Any one in alkene, polyethylene terephthalate, nylon, Pebax, polyurethane, polypropylene or latex or at least two
Material make.
9. the preparation method of the medicinal balloon catheter according to any one of claim 1-6, it is characterised in that methods described
For：By medicine or drug regimen and biostable polymer material mixing, by spraying or dip-coating even spread to sacculus table
Face obtains the medicinal balloon catheter；Or first by biostable polymer material by spraying or dip-coating even spread to ball
Capsule surface, then adsorbs medicine or drug regimen in coating surface, obtains the medicinal balloon catheter.
10. the medicinal balloon catheter according to any one of claim 1-7 in antirheumatic angiostenosiss apparatus should
With.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610988119.3A CN106621003A (en) | 2016-11-10 | 2016-11-10 | Drug balloon catheter and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610988119.3A CN106621003A (en) | 2016-11-10 | 2016-11-10 | Drug balloon catheter and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106621003A true CN106621003A (en) | 2017-05-10 |
Family
ID=58806415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610988119.3A Pending CN106621003A (en) | 2016-11-10 | 2016-11-10 | Drug balloon catheter and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106621003A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107485777A (en) * | 2017-09-06 | 2017-12-19 | 乐普（北京）医疗器械股份有限公司 | A kind of preparation method of the controllable medicinal balloon catheter of crystal, the medicinal balloon catheter being prepared and its application |
| CN109260526A (en) * | 2018-08-21 | 2019-01-25 | 陈绍良 | Jamaicin elutes sacculus figuration liquid and its application |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687066A (en) * | 2007-01-21 | 2010-03-31 | 汉莫提克股份有限公司 | Medical product for treating stenosis of body passages and for preventing threatening restenosis |
| US20110160698A1 (en) * | 2007-07-03 | 2011-06-30 | Hemoteq Ag | Balloon Catheter for Treating Stenosis of Body Passages and for Preventing Threatening Restenosis |
| CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
| CN102526861A (en) * | 2010-12-27 | 2012-07-04 | 微创医疗器械(上海)有限公司 | Interventional medical device |
| CN102573946A (en) * | 2009-10-16 | 2012-07-11 | 汉莫堤克股份有限公司 | Use of compositions to coat catheter balloons and coated catheter balloons |
| CN203763645U (en) * | 2014-03-21 | 2014-08-13 | 深圳脉动医学技术有限公司 | Balloon catheter |
| CN104661692A (en) * | 2012-08-23 | 2015-05-27 | 卡迪奥诺沃姆有限公司 | Balloon surface coating for valvuloplasty |
| CN105771005A (en) * | 2016-03-24 | 2016-07-20 | 乐普（北京）医疗器械股份有限公司 | Anti-rheumatic blood vessel stenosis drug-eluting stent and preparation method and application thereof |
-
2016
- 2016-11-10 CN CN201610988119.3A patent/CN106621003A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101687066A (en) * | 2007-01-21 | 2010-03-31 | 汉莫提克股份有限公司 | Medical product for treating stenosis of body passages and for preventing threatening restenosis |
| US20110160698A1 (en) * | 2007-07-03 | 2011-06-30 | Hemoteq Ag | Balloon Catheter for Treating Stenosis of Body Passages and for Preventing Threatening Restenosis |
| CN102573946A (en) * | 2009-10-16 | 2012-07-11 | 汉莫堤克股份有限公司 | Use of compositions to coat catheter balloons and coated catheter balloons |
| CN102526861A (en) * | 2010-12-27 | 2012-07-04 | 微创医疗器械(上海)有限公司 | Interventional medical device |
| CN102512747A (en) * | 2011-12-27 | 2012-06-27 | 微创医疗器械(上海)有限公司 | Medicine eluting balloon catheter |
| CN104661692A (en) * | 2012-08-23 | 2015-05-27 | 卡迪奥诺沃姆有限公司 | Balloon surface coating for valvuloplasty |
| CN203763645U (en) * | 2014-03-21 | 2014-08-13 | 深圳脉动医学技术有限公司 | Balloon catheter |
| CN105771005A (en) * | 2016-03-24 | 2016-07-20 | 乐普（北京）医疗器械股份有限公司 | Anti-rheumatic blood vessel stenosis drug-eluting stent and preparation method and application thereof |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107485777A (en) * | 2017-09-06 | 2017-12-19 | 乐普（北京）医疗器械股份有限公司 | A kind of preparation method of the controllable medicinal balloon catheter of crystal, the medicinal balloon catheter being prepared and its application |
| CN109260526A (en) * | 2018-08-21 | 2019-01-25 | 陈绍良 | Jamaicin elutes sacculus figuration liquid and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Halcox et al. | The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia | |
| Douglas et al. | A role for endogenous endothelin-1 in neointimal formation after rat carotid artery balloon angioplasty. Protective effects of the novel nonpeptide endothelin receptor antagonist SB 209670. | |
| US20090036352A1 (en) | Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof | |
| KR20040093058A (en) | N-(5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine coated stents | |
| JP2002539257A (en) | Increased drug bioavailability in the brain | |
| Miyauchi et al. | Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model | |
| JP2010195821A (en) | Prophylaxis and/or treatment of portal hypertension | |
| JP2003512431A (en) | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculatory disorders | |
| US12023421B2 (en) | Medical devices for continuous delivery of therapeutic agents | |
| AU2003227454B2 (en) | Medicament for therapeutic treatment of vascular disease | |
| JP2006524203A (en) | Use of dipyridamole or mopidamol for the treatment and prevention of thromboembolic diseases and disorders caused by thrombin over-formation and / or increased expression of thrombin receptor | |
| CN106621003A (en) | Drug balloon catheter and preparation method and application thereof | |
| US20050069518A1 (en) | Method for treating occlusive vascular diseases & wound healing | |
| CN206526381U (en) | A kind of medicinal balloon catheter | |
| Hsu et al. | Iloprost inhalation solution for the treatment of pulmonary arterial hypertension | |
| US20060013852A1 (en) | Use of organic compounds | |
| CN105771005A (en) | Anti-rheumatic blood vessel stenosis drug-eluting stent and preparation method and application thereof | |
| Edelman | Perivascular delivery of heparin regulates myointimal hyperplasia | |
| Zhang et al. | Annals of Medical Case Reports | |
| US20080139668A1 (en) | Pharmaceutical composition for obovatol for the prevention and treatment of restenosis | |
| JP2005511590A (en) | Pharmaceutical composition comprising an adenosine A1 / A2 agonist and a sodium hydrogen exchanger inhibitor | |
| Hofma et al. | Impairment of Distal Endothelium-Dependent Coronary Vasomotion after Sirolimus-Eluting Stent Implantation | |
| Sanada et al. | Optimal windows of statin use for immediate infarct limitation | |
| Malaise | Share this story: RELATED ARTICLES | |
| Porter et al. | Nanoparticle-based targeted delivery of therapeutics and non-invasive imaging of unstable endothelium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |